OPKO Health to Sell BioReference Lab Assets to Labcorp for $722 Million Plus Earnout
OPKO Health (OPK) agreed to sell BioReference's lab testing assets to Labcorp for $722M upfront, plus potential $150M earnout over 10 years. The deal, not contingent on financing, is subject to regulatory approval and may include a $28.88M termination fee if terminated for antitrust reasons. Closing is expected by Oct 14, 2026.
How this was made
The 30-second read
Why it matters
The transaction reshapes OPKO's portfolio and expands Labcorp's testing capabilities.
Market read
First‑report M&A deal with >$700M cash component; likely moves both stocks on announcement.
What to watch
Regulatory HSR clearance risk and potential termination fee could affect deal timing.
Background
OPKO Health is a diversified biopharma company; Labcorp is a leading clinical laboratory services provider.
Ticker impact
OPKO Health disclosed a $722M cash sale of BioReference lab assets to Labcorp, plus a potential $150M earnout.
likely upside as market prices in the cash proceeds and reduced operating exposure
The deal provides immediate liquidity and removes a non‑core business, which traders typically view favorably.
Market effects
Consolidation in the clinical pathology market may pressure peers.
U.S. healthcare sector sees modest re‑pricing.
Limited to U.S. lab services industry.
Counterpoint
If the earnout underperforms, Labcorp could face unexpected costs, turning the deal negative.
Key entities
- CompanyOPKO Health
Seller of BioReference lab assets.
- CompanyLabcorp
Buyer acquiring the assets.
